Related Experiment Video
Updated: Jun 26, 2026

Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser
Published on: May 5, 2020
[Effectiveness and safety of naftopidil for benign prostatic hyperplasia patients with overactive bladder symptoms]
Jing-ping Ge1, Jun Gong, Hong-qing Ma
1Nanjing MR Center of Urology and Andrology/Department of Urology, Nanjing General Hospital of Nanjing Military Region, Nanjing, Jiangsu 210002, China.
Objective:
To assess the effectiveness and safety of the alphala/d blocker naftopidil in the treatment of benign prostatic hyperplasia (BPH) patients with overactive bladder (OAB) symptoms.
Methods:
Fifty BPH patients with OAB symptoms were treated with naftopidil at the dose of 25 mg/d for 6 weeks. A self-controlled clinical trial was conducted. The effectiveness and safety of the drug were observed by comparing the International Prostate Symptom Scores (IPSS), quality of life indexes (QOL), maximum urinary flow rates (Qmax) , average urinary flow rates (Qave), voiding volumes (VV), blood pressures (BP) and heart rates (HR) obtained before and after the treatment.
Results:
After 6 weeks' medication, the 46 assessable cases showed an average decrease of 9.75 in IPSS (P < 0.01), 3.97 in voiding symptom score (P < 0.01), 5.78 in urinary storage symptom score (P < 0.01) and 1.95 in QOL (P < 0.01), and a mean increase of 4.29 ml/s in Qmax (P < 0.01), 3.75 ml/s in Qave (P < 0.01) and 55.12 ml/s in VV (P < 0.05). But no significant changes were observed in BP and HR. Only 1 patient (4.35%) experienced the adverse event of dizziness.
Conclusion:
The alphalA/D blocker naftopidil is both effective and safe in the treatment of BPH patients with OAB symptoms.
Related Concept Videos
Antihypertensive Drugs: Vasodilators
Urodynamic Studies: Uroflowmetry
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Urinary Tract Infection IV: Nursing Management
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care